Sugi Predict

Sugi Predict / Compounds / SCHEMBL1099189

SCHEMBL1099189

SCHEMBL1099189

C[C@]12C=CC(=O)N[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)O)CC[C@@H]12

nearest known ligand 0.78

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SRD5A1 P18405 11/20 0.74
▸ SRD5A2 P31213 10/20 0.74
▸ LMNA P02545 2/20 0.74
▸ CYP3A4 P08684 2/20 0.74
▸ CYP2C9 P11712 2/20 0.74
▸ CYP2C19 P33261 2/20 0.74
▸ ABCC4 O15439 1/20 0.74
▸ ABCB11 O95342 1/20 0.74
▸ ADORA3 P0DMS8 1/20 0.74
▸ CHRM1 P11229 1/20 0.74
▸ HSD3B1 P14060 1/20 0.74
▸ NFKB1 P19838 1/20 0.74
▸ MAPK1 P28482 1/20 0.74
▸ THPO P40225 1/20 0.74
▸ BLM P54132 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9233678 1.00 SRD5A1 (0.74) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL10000653 1.00 SRD5A1 (0.74) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL14397978 1.00 SRD5A1 (0.74) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL14477868 1.00 SRD5A1 (0.74) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL1108300 1.00 SRD5A1 (0.74) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL24503471 1.00 SRD5A1 (0.74) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL790006 1.00 SRD5A1 (0.74) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL13495833 1.00 SRD5A1 (0.74) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL790007 1.00 SRD5A1 (0.74) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL25772412 1.00 SRD5A1 (0.74) SRD5A1SRD5A2LMNACYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2238152-B1 PROCESSES FOR PREPARATION OF DUTASTERIDE GADOR SA (AR) 2015-02-18 — — EP claimed
US-8153648-B2 Solid and crystalline dutasteride and processes for preparation thereof GADOR S.A. (AR) 2012-04-10 — — US claimed
EP-2238152-A2 SOLID AND CRYSTALLINE DUTASTERIDE AND PROCESSES FOR PREPARATION THEREOF GADOR S.A. (AR) 2010-10-13 — — EP claimed
US-20090203724-A1 SOLID AND CRYSTALLINE DUTASTERIDE AND PROCESSES FOR PREPARATION THEREOF GADOR S.A. (AR) 2009-08-13 — — US claimed
WO-2009083258-A2 SOLID AND CRYSTALLINE DUTASTERIDE AND PROCESSES FOR PREPARATION THEREOF GADOR S.A. (AR) 2009-07-09 — — WO claimed
US-20050059692-A1 Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one DR. REDDY'S LABORATORIES LIMITED 2005-03-17 — — US claimed
JP-H10506411-A — — 1998-06-23 — — JP claimed
EP-0782582-A1 EPIMERS OF (22RS)-N-(1,1,1-TRIFLUORO-2-PHENYLPROP-2-YL)-3-OXO-4-AZA-5$g(a)-ANDROST-1-ENE-17$g(b)-CARBOXAMIDE PHARMACIA & UPJOHN S.p.A. (IT) 1997-07-09 — — EP claimed
WO-1997004002-A1 EPIMERS OF (22RS)-N-(1,1,1-TRIFLUORO-2-PHENYLPROP-2-YL)-3-OXO-4-AZA-5α-ANDROST-1-ENE-17β-CARBOXAMIDE PHARMACIA & UPJOHN S.P.A. (IT) 1997-02-06 — — WO claimed
JP-11100396-A — — None — — JP disclosed
CN-118119598-A Medicine for treating human tumor by eRF3a targeting protein degradation mechanism 苏州德亘生物医药有限公司 2024-05-31 — — CN disclosed
CN-111683950-B AhR modulators 伊迪亚生物科学有限公司 2024-04-16 — — CN disclosed
WO-2024066454-A1 DRUG FOR TREATING HUMAN TUMOR BY ERF3A TARGETED PROTEIN DEGRADATION MECHANISM 苏州德亘生物医药有限公司 2024-04-04 — — WO disclosed
CN-117801051-A Medicine for treating human tumor by eRF3a targeting protein degradation mechanism 苏州德亘生物医药有限公司 2024-04-02 — — CN disclosed
EP-0468012-A1 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION. ERBA CARLO SPA (IT) 1992-01-29 — — EP disclosed
US-5084574-A Reacting a 3-oxo-4-azasteroid with a silyating agent and quinone to form a double bond at the #1 ring position MERCK & CO., INC. (US) 1992-01-28 — — US disclosed
EP-0367502-A1 Methods of synthesizing benign prostatic hypertrophic agents MERCK & CO. INC. (US) 1990-05-09 — — EP disclosed
US-4845104-A Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones MERCK & CO., INC. (US) 1989-07-04 — — US disclosed
EP-0298652-A2 Dehydrogenation process and intermediates MERCK & CO. INC. (US) 1989-01-11 — — EP disclosed
EP-0271220-A1 Oxidized analogs of 17 beta-N-monosubstituted carbamoyl-4-aza 5 alpha-androst-1-en-3-ones MERCK & CO. INC. (US) 1988-06-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203724-A1 SOLID AND CRYSTALLINE DUTASTERIDE AND PROCESSES FOR PREPARATION THEREOF AR, CYP21A2, CYP4A22 SRD5A1 24/4885SRD5A2 20/4885LMNA 3146/4885
US-20050059692-A1 Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one NR5A1, CYP17A1, CYP19A1 SRD5A1 7/4885SRD5A2 8/4885LMNA 2644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.